Free tool
Drugs in development
Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations
Drugs in development
3,685
Not FDA-approved
In Phase 3
1,424
Highest phase reached
Matching your filters
28
28 drugs in development
Names, sponsors and conditions come from the trial records. Click a drug for its trials.
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- IBI362Phase 38 trials
Innovent Biologics (Suzhou) Co. Ltd. · Obesity, Overweight, Sleep Apnea
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- Saroglitazar MagnesiumPhase 35 trials
Zydus Therapeutics Inc. · Primary Biliary Cholangitis, Nonalcoholic Steatohepatitis, Fibrosis
- ALN-CIDEBPhase 34 trials
Regeneron · Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, MASLD
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- PemvidutidePhase 34 trials
Altimmune, Inc. · Alcohol-associated Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD)
- EfruxiferminPhase 33 trials
Akero Therapeutics, Inc · NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH/MASH
- pegargiminaseADI-PEG 20Phase 33 trials
Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
- PegozaferminBIO89-100Phase 33 trials
Roche (Genentech) · Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis, Severe Hypertriglyceridemia
- HSK31679Phase 32 trials
Haisco Pharmaceutical Group Co., Ltd. · MASH - Metabolic Dysfunction-Associated Steatohepatitis, NASH (Non-Alcoholic Steatohepatitis), Non-Alcoholic Steatohepatitis (NASH)
- IVA337LanifibranorPhase 31 trial
Inventiva Pharma · NASH - Nonalcoholic Steatohepatitis
- HRS-4729Phase 23 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Metabolic Dysfunction-Associated Steatohepatitis (MASH), Type 2 Diabetes, Overweight or Obesity
- ARO-INHBEPhase 22 trials
Arrowhead Pharmaceuticals · Metabolic Dysfunction-Associated Steatohepatitis, Obesity
- ECC4703Phase 22 trials
Eccogene · Adult Obesity, Weight Management, Metabolic Dysfunction-associated Steatohepatitis
- EfinopegdutideMK-6024, HM12525APhase 22 trials
Merck & Co. · Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
- HU6Phase 22 trials
Rivus Pharmaceuticals, Inc. · Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Fatty Liver
- NNC0194-0499Phase 22 trials
Novo Nordisk · Alcohol-related Liver Disease, Non-alcoholic Steatohepatitis
- AZD2693Phase 21 trial
AstraZeneca · Nonalcoholic Steatohepatitis
- BI 770371Phase 21 trial
Boehringer Ingelheim · Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH)
- ECC0509Phase 21 trial
Eccogene · Metabolic Dysfunction-associated Steatohepatitis
- efocipegtrutideHM15211Phase 21 trial
Hanmi Pharmaceutical Company Limited · NASH - Nonalcoholic Steatohepatitis
- QL2401Phase 21 trial
Qilu Pharmaceutical Co., Ltd. · Metabolic Dysfunction-associated Steatohepatitis (MASH)
- SNP-610Phase 21 trial
Sinew Pharma Inc. · NASH - Nonalcoholic Steatohepatitis
- TGM-312-SC01Phase 21 trial
Tangram Therapeutics Plc · Healthy Participants, MASH - Metabolic Dysfunction-Associated Steatohepatitis
- TQA2225AP025Phase 21 trial
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Non-alcoholic Steatohepatitis
- ZSP1601Phase 21 trial
Guangdong Raynovent Biotech Co., Ltd · Nonalcoholic Steatohepatitis (NASH)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.